[Antepartum prevention and postnatal therapy of respiratory distress syndrome].
The introduction of surfactant in the therapy of respiratory distress syndrome (RDS) reduced mortality and long term complications in very premature infants. Nevertheless, the obstetric management influences critically the outcome. In a prospective study of 116 premature infants with RDS treated with natural surfactant preparations after birth, mortality was significantly reduced by antepartum corticosteroid therapy suggesting a synergistic effect of corticosteroids and surfactant on the immature lung. It is assumed that a preventive administration of surfactant immediately after birth would benefit neonates at risk for RDS more than a delayed surfactant replacement after the development of RDS. But without a reliable assessment of fetal lung maturity before birth more than 50% of our premature infants with birth weights less than 1500 g would be exposed to surfactant unnecessarily. It is important that fetal asphyxia is avoided. Acquired respiratory distress syndrome occur even in premature infants after shock or meconium aspiration and may respond poorly to surfactant replacement. This is also the case in lung hypoplasia or perinatal infection, where the combined efforts of obstetricians and neonatologists are needed to attain better results.
Schrod
L
L
Kinderklinik und Poliklinik, Universität Würzburg.
Albert
P
P
Frauendienst-Egger
G
G
von Stockhausen
H B
HB
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D000075202:Contraindications; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D011247:Pregnancy; D011663:Pulmonary Surfactants / Q000008:administration & dosage*; D012127:Respiratory Distress Syndrome, Newborn / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D012307:Risk Factors
D000305:Adrenal Cortex Hormones; D011663:Pulmonary Surfactants
Präpartale Prophylaxe und postnatale Therapie des Atemnotsyndroms.